Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
-
Ulcerative Colitis Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$5.6 Billion by the end of ... Read More
-
Systemic Psoriasis Therapeutics
... at a CAGR of 8.1% over the analysis period 2024-2030. TNF Inhibitors, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$18.5 Billion by the end of ... Read More
-
Drug Discovery Informatics
... at a CAGR of 9.6% over the analysis period 2024-2030. Drug Discovery Informatics Software, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$3.4 Billion by the ... Read More
-
Focal Segmental Glomerulosclerosis
... at a CAGR of 6.6% over the analysis period 2024-2030. Primary Disease, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$17.9 Billion by the end of ... Read More
-
Immunosuppressants
... 13.8% over the analysis period 2024-2030. Calcineurin Inhibitors, one of the segments analyzed in the report, is expected to record a 15.9% CAGR and reach US$38.5 Billion by the end of the analysis period. Growth ... Read More
-
Label-free Array Systems
... at a CAGR of 5.6% over the analysis period 2024-2030. Surface Plasmon Resonance (SPR) Technology, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$1.8 Billion by ... Read More
-
Eye Allergy Therapeutics
... at a CAGR of 5.5% over the analysis period 2024-2030. Antihistamines, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$2.2 Billion by the end of the ... Read More
-
Desmopressin
... 5.6% over the analysis period 2024-2030. Injectable Solution Form, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$866.1 Million by the end of the analysis period. ... Read More
-
Chlamydia Infection Diagnostics and Therapeutics
... Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Chlamydia Infection Diagnostics, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$1.6 ... Read More
-
Hereditary Angioedema
... CAGR of 7.7% over the analysis period 2024-2030. C1 Esterase Inhibitors, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.5 Billion by the end of the ... Read More
-
Hepatitis Therapeutics
... CAGR of 3.7% over the analysis period 2024-2030. Hepatitis C Therapeutics, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.8 Billion by the end of the ... Read More
-
Vaginitis Therapeutics
... CAGR of 7.6% over the analysis period 2024-2030. Anti-Bacterial Product, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.7 Billion by the end of the analysis ... Read More
-
Gout Therapeutics
... CAGR of 13.4% over the analysis period 2024-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$4.7 Billion by the end of the analysis period. ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Neglected Tropical Diseases Diagnosis
... 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Conventional Method, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$5.4 Billion by the ... Read More
-
Osteoarthritis Therapeutics
... CAGR of 7.3% over the analysis period 2024-2030. Knee Anatomy, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.1 Billion by the end of the analysis ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Duchenne Muscular Dystrophy Drugs
... 2030, growing at a CAGR of 37.7% over the analysis period 2024-2030. Exon Skipping Therapy, one of the segments analyzed in the report, is expected to record a 42.6% CAGR and reach US$19.7 Billion by ... Read More
-
Pathology Instruments
... CAGR of 5.6% over the analysis period 2024-2030. Molecular Diagnostics Technology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the end of the ... Read More
-
Bipolar Disorder Therapeutics
... at a CAGR of 3.4% over the analysis period 2024-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Acute Myeloid Leukemia (AML) Therapeutics
... Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Cytarabine, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$592.7 Million by ... Read More
-
Antivenoms
... 7.4% over the analysis period 2024-2030. Snakes Species, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth ... Read More
-
Chiral Technology
... CAGR of 3.6% over the analysis period 2024-2030. Intermediates, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$8.2 Billion by the end of the analysis period. ... Read More
-
Amyotrophic Lateral Sclerosis
... at a CAGR of 19.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$345.9 Million While China is Forecast to Grow at 18.4% CAGR The Amyotrophic Lateral Sclerosis market in the U.S. ... Read More
Research Assistance
